1.The Role of Visceral Hypersensitivity in Irritable Bowel Syndrome: Pharmacological Targets and Novel Treatments.
Mohammad H FARZAEI ; Roodabeh BAHRAMSOLTANI ; Mohammad ABDOLLAHI ; Roja RAHIMI
Journal of Neurogastroenterology and Motility 2016;22(4):558-574
Irritable bowel syndrome (IBS) is the most common disorder referred to gastroenterologists and is characterized by altered bowel habits, abdominal pain, and bloating. Visceral hypersensitivity (VH) is a multifactorial process that may occur within the peripheral or central nervous systems and plays a principal role in the etiology of IBS symptoms. The pharmacological studies on selective drugs based on targeting specific ligands can provide novel therapies for modulation of persistent visceral hyperalgesia. The current paper reviews the cellular and molecular mechanisms underlying therapeutic targeting for providing future drugs to protect or treat visceroperception and pain sensitization in IBS patients. There are a wide range of mediators and receptors participating in visceral pain perception amongst which substances targeting afferent receptors are attractive sources of novel drugs. Novel therapeutic targets for the management of VH include compounds which alter gut-brain pathways and local neuroimmune pathways. Molecular mediators and receptors participating in pain perception and visceroperception include histamine-1 receptors, serotonin (5-hydrodytryptamine) receptors, transient receptor potential vanilloid type I, tachykinins ligands, opioid receptors, voltage-gated channels, tyrosine receptor kinase receptors, protease-activated receptors, adrenergic system ligands, cannabinoid receptors, sex hormones, and glutamate receptors which are discussed in the current review. Moreover, several plant-derived natural compounds with potential to alleviate VH in IBS have been highlighted. VH has an important role in the pathology and severity of complications in IBS. Therefore, managing VH can remarkably modulate the symptoms of IBS. More preclinical and clinical investigations are needed to provide efficacious and targeted medicines for the management of VH.
Abdominal Pain
;
Central Nervous System
;
Gonadal Steroid Hormones
;
Humans
;
Hyperalgesia
;
Hypersensitivity*
;
Irritable Bowel Syndrome*
;
Ligands
;
Pain Perception
;
Pathology
;
Phosphotransferases
;
Receptors, Adrenergic
;
Receptors, Cannabinoid
;
Receptors, Glutamate
;
Receptors, Opioid
;
Receptors, Proteinase-Activated
;
Receptors, Serotonin
;
Tachykinins
;
Tyrosine
;
Visceral Pain
2.The Protective Effect of Melissa officinalis L. in Visceral Hypersensitivity in Rat Using 2 Models of Acid-induced Colitis and Stress-induced Irritable Bowel Syndrome: A Possible Role of Nitric Oxide Pathway
Fatemeh DOLATABADI ; Amir H ABDOLGHAFFARI ; Mohammad H FARZAEI ; Maryam BAEERI ; Fatemeh S ZIARANI ; Majid ESLAMI ; Mohammad ABDOLLAHI ; Roja RAHIMI
Journal of Neurogastroenterology and Motility 2018;24(3):490-501
BACKGROUND/AIMS: The aim of present study is to estimate the effects of Melissa officinalis L. (MO) on visceral hypersensitivity (VH), defecation pattern and biochemical factors in 2 experimental models of irritable bowel syndrome (IBS) and the possible role of nitric oxide. METHODS: Two individual models of IBS were induced in male Wistar-albino rats. In the acetic acid model, the animals were exposed to rectal distension and abdominal withdrawal reflex, and the defecation patterns were determined. In the restraint stress model, the levels of TNF-α, myeloperoxidase, lipid peroxidation, and antioxidant powers were determined in the (removed) colon. Rats had been treated with MO, L-NG-nitroarginine methyl ester (L-NAME), aminoguanidine (AG), MO + AG, or MO + L-NAME in the mentioned experimental models. RESULTS: Hypersensitive response to rectal distension and more stool defecation in control rats have been observed in comparison to shams. MO-300 significantly reduced VH and defecation frequency in comparison to controls. VH and defecation pattern did not show significant change in AG + MO and L-NAME + MO groups compared to controls. Also, significant reduction in TNF-α, myeloperoxidase, thiobarbituric acid reactive substances (TBARS), and an increase in antioxidant power in MO-300 group was recorded compared to controls. AG + MO and L-NAME + MO groups showed a reverse pattern compared to MO-300 group. CONCLUSIONS: MO can ameliorate IBS by modulating VH and defecation patterns. Antioxidant and anti-inflammatory properties along with its effect on the nitrergic pathway seem to play important roles in its pharmacological activity.
Acetic Acid
;
Animals
;
Colitis
;
Colon
;
Defecation
;
Humans
;
Hypersensitivity
;
Irritable Bowel Syndrome
;
Lipid Peroxidation
;
Male
;
Melissa
;
Models, Theoretical
;
NG-Nitroarginine Methyl Ester
;
Nitric Oxide
;
Peroxidase
;
Rats
;
Reflex
;
Thiobarbituric Acid Reactive Substances